CymaBay Therapeutics SG&A Expense (TTM) Trends

CymaBay Therapeutics Inc (DELISTED) (CBAY:DL)

32.48 0.00 (0.00%) USD | NASDAQ | Mar 25, 16:00

SG&A Expense (TTM) Chart

Historical SG&A Expense (TTM) Data

View and export this data back to 2013. Upgrade now.

Date	Value
December 31, 2023	51.95M
September 30, 2023	39.39M
June 30, 2023	33.05M
March 31, 2023	27.35M
December 31, 2022	25.12M
September 30, 2022	23.97M
June 30, 2022	23.25M
March 31, 2022	23.89M
December 31, 2021	23.04M
September 30, 2021	22.12M
June 30, 2021	20.85M
March 31, 2021	17.54M
December 31, 2020	16.72M
September 30, 2020	16.07M
June 30, 2020	16.67M
March 31, 2020	17.99M
December 31, 2019	19.24M
September 30, 2019	18.86M
June 30, 2019	17.63M
March 31, 2019	16.67M
December 31, 2018	14.38M

Date	Value
September 30, 2018	13.12M
June 30, 2018	12.05M
March 31, 2018	12.06M
December 31, 2017	12.39M
September 30, 2017	12.33M
June 30, 2017	12.25M
March 31, 2017	10.88M
December 31, 2016	9.645M
September 30, 2016	8.602M
June 30, 2016	8.673M
March 31, 2016	8.743M
December 31, 2015	8.871M
September 30, 2015	9.407M
June 30, 2015	8.893M
March 31, 2015	8.274M
December 31, 2014	8.185M
September 30, 2014	7.944M
June 30, 2014	6.94M
March 31, 2014	6.446M
December 31, 2013	4.871M

SG&A Expense Definition

SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.

Read full definition.

SG&A Expense (TTM) Range, Past 5 Years

16.07M

Minimum

Sep 2020

51.95M

Maximum

Dec 2023

23.93M

Average

22.12M

Median

Sep 2021

SG&A Expense (TTM) Benchmarks